Abstract: Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients.

Abstract: Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients.

Abstract: The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Abstract: The present invention provides an improved integrated system for biological marker identification. The system uses Microvolume Laser Scanning Microscopy (MLSC) in order to measure patterns of expression of biological markers in biological fluids. The system includes improved instrumentation for performing MLSC, and also includes improved particle detection and analysis methods. The system further comprises an informatics architecture for the analysis of data obtained from the MLSC in tandem with other medical information.

Abstract: A system for laser scanning provides spectral flexibility needed for the spectroscopic monitoring of highly multiplexed samples, such as cellular and particle assays in whole blood or other suspensions. In accordance with embodiments of the present invention, the system comprises a scanner to direct an excitation laser through a sample, an objective to collect light emitted by the sample in response to the excitation laser, a spectrograph to disperse the emitted light over a plurality of wavelengths as a spectrum, and a charge coupled device for detecting the spectrum. The system can be used with samples having a variety of reporter tags, including one or more SERS tags, fluorescent organic and protein tags, and quantum dot tags. A laser scanning apparatus and method of using the same is also provided.

Abstract: The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Abstract: The present invention provides an improved integrated system for biological marker identification. The system uses Microvolume Laser Scanning Microscopy (MLSC) in order to measure patterns of expression of biological markers in biological fluids. The system includes improved instrumentation for performing MLSC, and also includes improved particle detection and analysis methods. The system further comprises an informatics architecture for the analysis of data obtained from the MLSC in tandem with other medical information.

Abstract: Novel biological markers indicative of the action of an anti-inflammatory or immunosuppressive drug can be used to evaluate drug efficacy and compare local and systemic drug effects. They can also aid in comparison of different drugs, doses, and delivery routes. The biological markers include cell populations, cell surface antigen expression levels, and soluble factor concentrations. Measurement values of the novel biomarkers were shown to change significantly in allergic, atopic asthmatic, and healthy subjects after administration of prednisone.

Abstract: The present invention provides an improved integrated system for biological marker identification. The system uses Microvolume Laser Scanning Microscopy (MLSC) in order to measure patterns of expression of biological markers in biological fluids. The system includes improved instrumentation for performing MLSC, and also includes improved particle detection and analysis methods. The system further comprises an informatics architecture for the analysis of data obtained from the MLSC in tandem with other medical information.

Abstract: A database-driven cytometry network allows for acquisition, analysis, and viewing of large amounts of cytometry data from multiple cytometers. Data from multiple instruments are uploaded to a database, where combined compensation and calibration matrices are applied automatically to correct for both spectral overlap among acquisition channels and instrument-dependent variations. The resulting instrument-independent data are gated automatically using common template gates. A user at a client computer can view and perform statistical analyses on any desired subset of the gated data.

Abstract: Multiplexed immunoassays are performed using cells expressing on their surface capture agents such as antibodies or antibody fragments. The cells serve as the solid phase supporting the capture agent and also express identifiers encoding the nature of the capture agent, allowing the cells to be used in multiplexed assays. For example, the identifiers can be internally expressed fluorescent proteins or externally expressed proteins that bind to tagged antibody reagents. Analyte detection and quantification are performed by detection antibodies binding to bound analyte or by detection proteins expressed by the cell in response to analyte binding. By encoding capture, identification, and analyte detection functionalities within the cell, expensive and time-consuming steps of antibody preparation, purification, and coupling to a solid phase are eliminated, making the cells advantageous over antibody-coupled beads currently used in multiplexed immunoassays.

Abstract: The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Abstract: Novel biological markers indicative of the action of an anti-inflammatory or immunosuppressive drug can be used to evaluate drug efficacy and compare local and systemic drug effects. They can also aid in comparison of different drugs, doses, and delivery routes. The biological markers include cell populations, cell surface antigen expression levels, and soluble factor concentrations. Measurement values of the novel biomarkers were shown to change significantly in allergic, atopic asthmatic, and healthy subjects after administration of prednisone.